934664-27-4

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 2-(1-(benzyloxycarbonyl)-3-hydroxyazetidin-3-yl)piperidine-1-carboxylate is used as a building block in organic synthesis for the preparation of various pharmaceuticals and biologically active molecules. Its unique structure allows it to be a versatile component in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, tert-Butyl 2-(1-(benzyloxycarbonyl)-3-hydroxyazetidin-3-yl)piperidine-1-carboxylate serves as an important compound for studying the properties and interactions of heterocycles. Its presence in various molecular structures can provide insights into the design and synthesis of potential drug candidates with improved pharmacological properties.

Upstream product

• 388077-74-5 rac-N-(tert-butoxycarbonyl)piperidine-2-carboxamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 105258-93-3 N-(Benzyloxycarbonyl)azetidin-3-one 

Downstream Products

• 934665-56-2 (R,S) tert-butyl 2-{1-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl]-3-hydroxy-3-azetidinyl}-1-piperidinecarboxylate 
• 934662-91-6 cobimetinib 
• 1369665-02-0 (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemifumarate 
• 934665-56-2 tert-butyl (S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzoyl]-3-hydroxy-3-azetidinyl}perhydropyridine-1-carboxylate 
• 934660-93-2 [14C]-GDC-0973 
• 934666-39-4 1,1-dimethylethyl (2R)-2-(3-hydroxyazetidin-3-yl)piperidine-1-carboxylate 
• 934666-39-4 1,1-dimethylethyl (2S)-2-(3-hydroxyazetidin-3-yl)piperidine-1-carboxylate 
• 934665-54-0 1,1-dimethylethyl (2R)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 
• 934665-55-1 1,1-dimethylethyl (2S)-2-(3-hydroxy-1-{[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-1-carboxylate 
• 934666-39-4 (R,S) tert-butyl 2-(3-hydroxy-3-azetidinyl)-1-piperidinecarboxylate 
• 934665-53-9 1,1-dimethylethyl (2S)-2-(1-{[(phenylmethyl)oxy]carbonyl}-3-{[(2R)-3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-1-carboxylate 
• 934665-52-8 1,1-dimethylethyl (2R)-2-(1-{[(phenylmethyl)oxy]carbonyl}-3-{[(2R)-3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

PROCESS FOR THE PRODUCTION OF COBIMETINIB

The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt content.

NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS

The invention provides novel substituted 6-arylamino pyridone carboxamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, poly- morph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.

METHODS OF USING MEK INHIBITORS

The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.